Last $2.01 USD
Change Today -0.02 / -0.99%
Volume 24.3K
PTIE On Other Exchanges
Symbol
Exchange
PTIE is not on other exchanges.
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Pain Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $3.5 million, or $0.08 per basic and diluted share, compared to a net loss of $0.8 million, or $0.02 per basic and diluted share in last year. The company reported operating loss of $3.5 million compared to $0.8 million for the last year. For the nine months, the company reported net loss of $10.2 million, or $0.23 per basic and diluted share, compared to a net loss of $1.5 million, or $0.03 per basic and diluted share and operating loss of $10.3 million compared to $1.5 million for the last year.

Pain Therapeutics Inc. - Special Call

To discuss regain of full rights to REMOXY

Pfizer to Discontinue Agreement on REMOXY(TM) (oxycodone) Extended-Release Capsules CII with Pain Therapeutics

Pfizer Inc. has notified Pain Therapeutics Inc. that it has decided to discontinue its agreement to develop and commercialize REMOXY(TM) (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date.

Pain Therapeutics Inc., Q3 2014 Earnings Call, Oct 30, 2014

Pain Therapeutics Inc., Q3 2014 Earnings Call, Oct 30, 2014

Pain Therapeutics Inc. Announces to Eliminate the Position of Chief Scientific Officer, Effective October 31, 2014

Pain Therapeutics Inc. will eliminate the position of Chief Scientific Officer. As a result, after October 31, 2014 Grant Schoenhard, Ph.D. will no longer be an employee of the Company, effective October 31, 2014. In connection with this change, the Company and Dr. Schoenhard have entered into a Scientific Consulting Agreement whereby Dr. Schoenhard will continue to provide his expertise to the Company as an independent consultant for an initial term of one year. The Company will direct only the result of his work as an independent consultant and not how his services are provided to the Company. Dr. Schoenhard anticipates he will continue to serve on the Company's Scientific Advisory Board and the Company's Patent Committee during the initial term of his consulting services.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $2.01 USD -0.02

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies
 

Industry Analysis

PTIE

Industry Average

Valuation PTIE Industry Range
Price/Earnings 4.1x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 4.1x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.